科倫藥業(002422.SZ)一季度淨利潤預增630.95%-813.69%
格隆匯 4 月 14日丨科倫藥業(002422.SZ)公佈,預計2021年第一季度歸屬於上市公司股東的淨利潤1.6億元-2億元,同比增長630.95%-813.69%。業績變動原因如下:
1.2020年一季度受疫情影響,產品終端使用量大幅減少,隨着國內疫情不斷好轉,2021年一季度產銷量基本恢復,公司輸液、非輸液製劑及新產品銷量同比增長;
2.伊犁川寧產品受市場環境影響,價格恢復性上漲,利潤同比增加;
3.公司持續加大創新投入,研發費用較同期增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.